5 results about "Thiazide derivatives" patented technology

The invention provides a diaphragm and a secondary battery, and belongs to the technical field of secondary batteries, and the diaphragm comprises a base membrane and a coating. Wherein the coating is arranged on one surface, facing the positive pole piece, of the base film, and the coating comprises an electroactive material and a binder; the electroactive material comprises at least one of a quinone derivative, a phenazine derivative, an imide derivative and a phenothiazine derivative. The electroactive material in the diaphragm coating can be dissolved in the electrolyte after the environment temperature reaches the thermal safety critical temperature, and reacts with the positive and negative active materials, so that the charge state of the battery is quickly reduced, and the thermal runaway of the battery is inhibited or even avoided.

The present invention relates to a polysubstituted imidazolo[4,5-c][1,2]thiazine derivative and a use of an agent comprising same as an active agent, which is useful for infectious diseases associated with vascular inflammation caused by HMGB1 protein activity. It has been found that the polysubstituted imidazolo[4,5-c][1,2]thiazine derivative of the present invention increases the sepsis survival rate as a result of searching for antiseptic effects through CLP-induced sepsis animal experiments. Accordingly, the agent comprising the polysubstituted imidazolo[4,5-c][1,2]thiazine derivative or a pharmaceutically acceptable salt thereof as an active agent may be advantageously used as a therapeutic agent for infectious diseases and vascular inflammatory diseases including sepsis caused by HMGB1 protein activity.

The invention belongs to the technical field of medicines, and particularly relates to an alpha-lipoic acid phenothiazine derivative as well as a preparation method and application thereof. The structural formula of the alpha-lipoic acid phenothiazine derivative is as shown in formula 1. The invention provides an alpha-lipoic acid phenothiazine derivative, and research finds that the alpha-lipoic acid phenothiazine derivative shows good anti-inflammatory activity which is slightly superior to that of alpha-lipoic acid. Moreover, the effect of the pharmaceutical composition is better than that of a positive drug edaravone clinically used in cerebral arterial thrombosis at present, and the pharmaceutical composition can be further developed into a treatment drug applied to ferroptosis related diseases. .

Provided is a method for using a phenothiazine derivative compound, in which, in a synthetic polymer material produced by addition polymerization of a polymerizable unsaturated monomer, the polymerizable unsaturated monomer constituting the material is copolymerized with a phenothiazine derivative compound represented by general formula [I] in order to prevent oxidative degradation of the synthetic polymer material. The compound can be copolymerized with various polymerizable unsaturated monomers because the specific polymerization inhibition effect of the phenothiazine compound is reduced. In the general formula [I], R1 is a monovalent aliphatic hydrocarbon group having 1-10 carbon atoms, and R2 is a hydrogen atom or a methyl group.

The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.